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Treatment of human vascular smooth muscle cells (SMC) with human ~-thrombm greatly increased DNA synthesis and cell proliferation. Both 
the integrity, of the catal)'tie site and that of [he amon binding exos:te were required for expresston of thin activity. Experiments employing Northems 
indicated reduction of c.fo.~ expression as well as a time-dependent i due,on of platelet-denved growth factor-A (PDGF-A) gene by thrombin. 
The thrombm mitogenic activity wa~ potentiated by PDGF-BB, msuhn and the vasoconstrictor pept~de endothehn-I suggesting ~ynergism by 
convergence of intracellular growth-promoung ~lgnals. SMC treatment with pertu,.sis toxin and forskolin indicated that the mitoe, emc activity of 
thrombm may be induced via signal transduction mechanlsm(s) involving change~ aa cAMP levels and acuvatlon ofa G,.hke protein. These results 
suggest hat thrombm ma), play a functional role in the regulation of human vabeular SMC prohl'eration. 
Platelet-derived growth factor reduction, Thrombm; Smooth muscle cell, Prohferation, Pertussm toxin; G protein; Cyclic AMP 
1. INTRODUCTION 
The properties of thrombin as a serine protease (EC 
3.4.21.5) and its role in the blood coagulation-fibrinol- 
ysis cascade, have been well characterized [1-4]. Throm- 
bin can also contribute to the thrombogenic properties 
of the vessel wall. Fibrin-bound thrombin is protected 
from inactiva,ion by heparin-antithrombin 1II, and 
there is a sustained release of cx-thrombin after blood 
clotting during re-endothelialization a d enzymatic 
degradation of the blood clot [5~6]. Furthermore, 
thrombin can induce gap formation between adjacent 
endothelial cells [7], and it can bind to subendothelial 
extracellular matrix (ECM) leaving the enzyme catalyttc 
site intact [~,9]. Thrombin is chemotactic for monocytes 
[10], it initiates proliferation of a number of cells [11,12], 
it alters ECM composition and promotes endothelial 
cell adhesion and spreading 19,13,14]; it induces the ex- 
pression and release of platelet-derived growth factor 
(PDGF) from endothelial cells [15,16] and acts as a 
vasoconstrictor for vascular SMC [17]. 
The !mpor~.ance of the catalytic activity in thrombin 
and its rok in vascular emodelling have become issues 
of controversy with regard to vascular SMC prolifera- 
tion, Although in neon:ttal rat vascular-SMC, g-throm- 
bin was shown to be mitogenie [18,19] and to induce 
c-myc and PDGF°A chain expression [20], in adult rat- 
SMC, ~x-thrombin and its various thrombin forms were 
shown to induce protein synthesis and growth-related 
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signals including c-fos mRNA expression but not DNA 
synthesis [21,22]. In contrast, immobilized, non-enzy- 
matically active thrombin was shown to induce SMC 
proliferatton [23]. In the present work we demonstrate 
that human cz-thrombin is a potent mitogen for adult 
human vascular-SMC; that it synergises with PDGF or 
other mitogens and that it induces the expression of 
PDGF-A chain gene. The evidence that the potency of 
thrombin as a mitogen depends on both, the catalytic 
and anion exosite sites as well as the involvement of a 
pertussis toxin sensitive (;-protein in the signal 
transduction mechanism(s) of thrombin are discussed. 
2. MATERIALS AND METHODS 
2 1 Matertal~ 
Purified human a-thrombm (specific acuvlty 3,000 U/rag). pertussis 
toxin, cychc adenosine monophosphate (cAMP), 3',5'-cAMP-depend- 
ent protein kmase, for~kohn, i BMX and anti-ct-SMC actin antibodle~ 
were from Sigma, r~.Phe-Pro.Arg-CH_,Cl (PPACK) from Calbiochem. 
[~H]Thymldme (5mCL/mmol), [~H~cA MP (24 Ct/mmol)and [~-'P]dCTP 
(3,000 Ct/mmol) were from Amc, r.~ham; PDGF-BB and fibroblast 
growth factor (FGF / were from Bachem, insulin was from Boehrmger 
and endothe![n-I was from Peninsula Lab. All other chemicals and 
culture media v, erc obtained from source~ as specHied or were of the 
highest purity available commercially. Purified human 0~-thrombm 
was characterized by SDS-PACIE, and ~ts ertz~mat~c a ttvity deter- 
miaed as described [2]. 7-Thrombin prepared by autocatalytic degra- 
dation of human 0~-thrombm [24] retained esterase activity but had 
only 1 6 U/mg specific lotting aeuwty. PPACK-~t-thrombin was pre- 
pared as described [25] and dialyzed against ~erum.free (SF) DMEM 
prior to use. 
2.2. Cells attd cell culture 
aP  ~e~lalt~rl  Human S . . . .  were . . . . . . . .  from sections of abdominal normal 
aorta obtained from kidney transplant donors (10-45 years of age). 
The aoruc tissue w, as transferred into DMEM supplemented with 100 
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lU/ml pentcilhn, 100 ltgtml ~treptomycm sulplaat¢, 100 ~g/ml neomy- 
cin and 2.5 ~'g/ml fungizone (Gibco) Dissected medial tissue was finely 
minced, rin~ed and disested under constant agitation (18-20 h, 37°C) 
m DMEM 15 mM HEPES (Flow Lab) with 0.1% collagenase Type 
I1 (Worthington) and 0.05% elastase Type I (Sigma) supplemented 
with 10% FCS. Digested eelh were cultured in L-slutamine/antibiotics- 
~upplemented DMEM/HEPES and 20% FCS which was reduced 1o 
10% after the second passage Cells were sabcultured at a ~plit ratio 
of 1'4, chai'actenzed [26] and used between passages 2-8. Two or three 
cell cultures were used for each experiment. 
2.3. cAMP meaaurement 
After treatment of g~owth-arre~ted c lh (see below) under various 
condtfions, cAM P levels were measured inextracts of cells treated with 
ethanol (4oc, 30 min). After removal of precipitated protein by cen- 
trifugation, the ethanol extracts were dried by evaporatton (under 
vacuum), resuspended in 50 mM Tris-HCI, 4 mM EDTA pH 7.0 and 
assayed as described pievloa~ly [27]. Protein was estimated using the 
Pierce protein-assay reagent kit. 
2.4. DNA s)vtthe~ts/cefl proliferation 
For DNA synthesin, SMC were plated (96-well plates, 1 x 10 ~ cells 
per well) in DMEM/15 mM HEPES supplemented with 10% FeB and 
antibiotics. Upon eonfluency, ceils were 8rowth arrested (48 h; 0.5% 
FCS) Unless otherwise stated, DNA synthesis was measured 40 h 
post.stimulation bylabelling (24 h) ~vith 1 ,uCl [~H]tbymidlne prior to 
harvesting the cells (Brandel harvester; Whatman GF/B filtet~). For 
experiments with pertu~si~ toxin cells were pro-incubated for 6 h with 
the indicated concentration f the toxin in SF medium before stimula- 
tion with growth factors. For cell proliferation, SMC were plated 
(24-well plates; l × l0 ~ cells per well) in DMEM/HEPES, 10% FCS 
and 24 h late~ growth arrested as above. Ceil numbers were mcabured 
4 days later using a Coulter Counter. 
2 5. Northern hybrMm..atton 
RNAs were prepared flom SMC (,'-I0 ? ceils) according to the 
method of Wisnievski ct ai, [28]. For Northern hybridization RNA (10 
/-/8) wa~ electrophoresed through agarose gel (1%), transferred to 
Hybond membrane filt~rs and hybridized with either the c.fos (pf22) 
DNA probe [29]° it c-m),c probe containing oxen 2'-3' coding region 
[30] or a PDGF-A probe ¢ontamin~ the HmdlI1-Sacl fragment (640 
bp) [31], Ti~= DNA probe~ were labelled with [~:P]dCTP by random 
priming as described [32]. The pGd-T-SB probe of glueose-6-phos- 
phate dehydrogenase (G6PD) [33] was used as a control in all 1North- 
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ern~. Removal of radiolabelled probe for rehybridization of mem- 
bJanes was as described [32] 
3, RESULTS AND DISCUSSION 
Med ia  SMC migrat ion  and  pro l i fe ra t ion  into the  in-  
tima in response to chemoattractants and growth fac- 
tors released at the site of vascular injury, have been 
considered as major contributors to the proliferative 
nature and progression of atherosclerotic lesions [34]. 
Such lesions are often occluded by a thrombus [35] 
which during lysis can become the source of ¢nzymati- 
cally active thrombin [24]. This potential availability of 
thrombin to VSMC has placed particular emphasis on 
its post-clotting role in p romoHng SMC proliferation. 
Fig. l shows that in SF  medium, enzymatically active, 
human ~-thrombin induces DNA synthesis in human 
aortic SMC (Fig. l a) in a dose-dependent manner with 
maximal stimulation obtained between 2 and 4 U/ml 
(20-40 nM). The y-thrombin concentrations used were 
based on the original concentration of cz-thrombin; this 
preparation retained little clotting activity as a result of 
autocatalytic cleavage that lowers the affinity of the 
fibrinogen binding exosite [I-4,24]. 7-Thrombin as 
compared to 0c-thrombin and when used at equimolar 
concentrations was found to be less potent in stimulat- 
ing ['~H]thymidine uptake (Fig. l a). 0c-Thrombin inac- 
tivated at the catalytic site by the D-Phe-Pro-Arg-chlo- 
romethyl ketone inhibitor [25], PPACK-thrombin,  
failed to induce DNA synthesis at the same range of 
concent ra t ions  (F ig .  la )  suggest ing  that  an  in tact  cata -  
lyt ic  site and  a h igh-a f f in i ty  an ion-exos i te  are impor tant  
fo r  the mi togen ic  act iv i ty  o f thrombin  in agreement  w i th  
data  obta ined  in f ib rob las ts  [24]. As  expected f rom the  
[3H] thymid ine  uptake  data ,  there  was  a s ign i f icant  in- 
crease (36 + 2%) in cell numbers upon 4-day exposure 
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Fig I. Thrombm induces DNA synthesis .'rod prohlbration of human aortic smooth muscle cells. La) inducuon of DNA syntnem~ m SF medium 
by ~t-thrombin (e), 2,-thrombm (o) or PPACK-ct-thrombm ([]). (b) Cell proliferation induced by 2 U/ml thrombin in $F medium supplemented 
with or without 2% FBP Data are expressed a~ a percentage ofcontrol cells incubated for the same time period in SF medium alone, and represent 
the mean + S.E.M. (n = 4) of one of thre= or four representative cxp,~nm~nts. P values were calculated using Student's t-test analysis. 
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Fig. 2. Thrombin induces the expression of PDGF-A chain gene. 
Northern blots ofe, qual amounts (10/aS) of total ecitular RNA were 
hybridizgd with 0.65 kb PDGF-A (a,b), 2 kb c-los (c) or i .3 kb e-myc 
(d) probes. All blots were stripped and rehybridized with a 0.53 kb 
G6PD probe used as internal control as shown for c-myc (d). Growth- 
arrested, confluent aortic SMC were exposed for the times indica~l 
to 5 U/ml intact ~-thrombin (a,b risht lanes, and c,d) or PPACK- 
inactivated thrombin (b left lanes) prior to harvesting thecelis for total 
RNA extraction. (e) The kinetics of DNA synthesis in growth-ar- 
rested, confluent aortic SMC induced by 1 U/ml human ~-thrombin 
(o), 10% FCS (r~) or 5 ns/ml PDGF-BB (:Q, were measured at the 
indicated post-induction times by 4 h pulse labelling the cells with 
[3H]thymidine as deserib~-d in section 2. Re,~ults are from one of three 
representative experiments a--d), or the mean +_ S.E.M. (n = 4) of one 
of four representative experiments (e ) .  
of aortic SMC to thrombin as compared to quiescent 
control cells (Fig. 1 b). Exposure to fetal bovine plasma 
(FBP) (platelet poor plasma; with no esterase activity) 
increased cell numbers to 72 -+_ 1% and co-exposure with 
thrombin to 151 + 12% (Fig. lb), indicating a synergis- 
tic effect between thrombin and the growth promoting 
activity of plasma. 
Thrombin induced the expression of PDGF-A chain 
mRNA which, as indicated by the time course of expres- 
sion in Fig, 2a, peaked and fell significantly much later 
than previously reported for thrombin or other mito- 
gens [20]. PDOF-A expression levelz normalised for 
(36PD mR1NA levels used as control, showed that 
PPACK-inaetivated thrombin stimulated mRNA ex- 
pression by 2-fold (Fig. 2b, left lanes) as compared to 
active ~-thrombin which elevated mRNA levels by 5- 
fold after 10 h of stimulation (Fig. 2b, right lanes). The 
low stimulation of PD(3F-A mRNA expression by this 
preparation of PPACK-inactivated thrombin was attri- 
buted to a residual mitogenic activity (data not shown) 
invariably seen in some preparations as a result of in- 
complete inactivation of thrombin due to the rapid hy- 
drolysis of the chloromethyl ketone inhibitor. Although 
we cannot exclude the induction of expression of other 
growth factors, the kinetics of PDGF-A gene induction 
by thrombin and the delay for throtnbin-induced maxi- 
mal DNA synthesis as compared to FCS or PDGF-BB 
(Fig. 2a vs. 2e) are similar to those of the autocrine 
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PDt3F-AA loop induced in VSMC by interleukin. 1 [36] 
or transforming 8rowth factor-fl [37]. Catalytically ac- 
tive thrombin induced the expression of c-los (Fig. 2c) 
in accordance with the action of other known mitogens 
and in agreement with other studies on thrombin [21]. 
c-tnyc expression appeared to peak at 8 h (Fig. 2d) 
which is much later than has been observed for throm- 
bin in fibroblast cells (l h) or in neonatal VSMC (4 h)0 
or for other mito/~ens [20,39,40]. When it is compared 
with the time course of PDGF-A mR.NA expression, 
our data support hat the mediation ofc-myc expression 
is possibly via atatocrine growth factor activity. There- 
fore, in human YSMC thrombin may affect ceil growth 
by direct induction of early growth-related signals as 
well as via induction of expression of growth factor 
activity. Variations in experimental conditions, the con- 
formation of thrombin or variations in growth factor 
receptor types and numbers may account for variations 
on thrombin m~togenicity in the various cell types ob- 
served previously [18-24]. Similarly, species pecific dif- 
ferences may account for the earlier induction of c-myc 
and PDGF-A expression (4-7 h) observed in neonatal 
rat VSMC [20]. 
The DNA synthesis induced by thrombin was poten- 
tiated by insulin, which by itself tailed to induce DNA 
synthesis in human VSMC, or by PDGF-BB and the 
vasoconstrictor peptide ndothelin [41] which were not 
mitogenie at the low concentrations tested here (Fig. 
3a-¢). This potentiation was more apparent at higher 
concentrations of' thrombin for insulin and at lower 
concentrations for the other ligands (Fig. 3) suggesting 
synergism via several mechanisms of signal transduc- 
tion0 and/or that potentiation may depend on the level 
of concentration of second messenger(s) induced by 
thrombin. These observations are in agreement with the 
evidence in support of cooperative effects on cell prolif- 
eration of G protein-dependent signal pathways and 
growth factor-receptor tyrosine kinases [42] and the 
fact that thrombin and endothelin have similar mite- 
genie and vasoconstrictor activities in SMC [17,43]. 
Pertussis toxin treatment attenuated the thrombin- 
induced DNA ~ynthesis n the range of thrombin con- 
centrations shown, and this attenuation was dependent 
on the concentration f the toxin (Table I) in agreement 
with the findings reported previously for Chinese ham- 
ster lung fibroblasts [44]. Pertussis toxin (10 ng/ml) 
treatment ofcells did not affect heir mitogenic response 
to PDGF-BB or FGF as compared to umreated ce!ls 
(data not shown) suggesting that the effect of pertussis 
toxin on the thrombin mitogenic activity is specific. 
Since pretreatment with forskolin which is believed to 
stimulate adenylate yclase directly [45] and was shown 
to inhibit endothelial PDGF-induction by thrombin 
[46], also inhibited DNA synthesis induced by thrombin 
(Table I), our data indicates the involvement era G,-like 
protein which regulates negatively adenylate cyelase as 
also reported for pmtelets [47]. The involvement of a 
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F~g. 3. Thrombm ~ynergizes with other g~owth promoting factors 
Dose-dependent mductton ol" DNA ~ynthems in aortic SMC by human 
;¢-thrombin, wa~ measured in the absence (o) or pre~ene¢ (e) of(a) 0.5 
n~/ml PDGF.BB, (b) 1/~8/ml insulin, or (e) 2.5 n~/ml endothehn-I as 
described in section 2. Values represent the mean ± S.E.M 0z = 4) of 
one ot" 3 or 4 representative experiments. 
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Table I 
Thrombm effect on cAMP levels, and the el'feet ol'pertussis toxin and forskohn on thrombin-mdueed DNA s2cnthesis m human aortic smooth muscle 
cells 
Thrombin cAMP ~ 
(U/ml) (pmol/mg protein) 
DNA synthesis b (dpm) 
Pertussis toxin (ng/ml) Forskohn CaM) 
0 1 10 0 10 
0.00 94.4 +_ 2.4 766 ± 8fl 571 +_ 45 474 -L-_ 28 700 -e 80 635 +_ 45 
0.10 nd ~ 2,358 __. 259 1,274 ± 139 939 +_- 162 2.860 + 2,45 815:1:75 
0.5 85.3 _ 3.7 2,922 ± 80 1,617 __. 178 1,149 +_ 235 nd nd 
1 nd 4,439 ± 600 1,995 ± 235 1,579 + 69 4.645 +_ 80 1,255:1:305 
2 75.4 _+ 2.1 5,439 z 1,679 2,874 +_ 287 1,981 + 28 nd nd 
5 69.2 + 2.6 nd nd nd nd nd 
'~cAMP levels m confluent, growth-arrested SMC were measured 60 mm post-~tlmulation with human g-thrombin in SF medmm m the presence 
of 100 ,aM IBMX. cAMP levels m ¢oauol cells were measured after 60 min meubatmn w~th 100/.tM IBMX m SF medium. 
bThrombm-mduced DNA ~),nthenis was measured as m section 2 w~thout or with pre-treatment (6 h) ofcells w~th pertussm toxin or in lhe ab~nge 
or presence oi' fo~skolin added ~mmedtately before thrombin. Results represent the mean __. S E.M. (tl = 4) of one of 2 or 3 repre~ntative 
experiments. 
"ad = not determined. 
G-like protein was also suggested by the thrombin inhi- 
bition of  cAMP levels which we were able to observe 
after inclusion of  the phosphodiesterase inhibitor 
IBMX (Table I). However, since the direct coupl ing of  
the thrombin receptor to a G,-like protein has yet to be 
demonstrated, we cannot  exclude the possibility of  an 
indirect effect on the activity of  adenylate cyclase via 
thrombin receptor coupl ing to additional pertussis 
toxin-sensitive or -insensitive G proteins and/or  induc- 
tion of  other pathways which may co-operate in the 
mediation of DNA synthesis as suggested previously for 
other cell types [18-24,44,46]. Recent findings support  
the possibility of  receptor coupling with more than one 
G protein [48]. Alternatively, there may be more than 
one type of  thrombin receptor the expression o f  which 
as well as coupling to signal transducers may differ 
between cell types. The requirement for an intact cata- 
lytic site of  thrombin and the involvement o f  the anion 
e~osite for the induction of  DNA synthesis, are in agree- 
meat with the novel thrombin-regeptor activation mech- 
anisrn proposed recently [49-51]. Similarly, the signal 
transduction mechanism of  thrombin receptor activa- 
tion indicated by our data, are in agreement with recep- 
tor coupling to a G protein proposed from molecular 
cloning expression and transfeetion studies of  the 
human thrombin receptor [49-51]. 
The induction of  growth factor expression like PDG F 
in human vascular SMC by thrombin, and the thrombin 
potentiation of  growth factor- or vasoconstr ictor-mite- 
genie activity emphasize the growth factor-l ike proper- 
ties of  this sorine proteinase nzyme. It also provides a 
new perspective from which to consider (a) the mite- 
genie and proliferative effects of  thrombin as a link 
between blood clotting and wound healing, and (b) the 
post-clotting contributions o f  thrombin to atherogene- 
sis. 
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